Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice

Kidney International

Volumn 92, Issue 4, 2017, Pages 909-921

  Zhang, Hongyu ^a   Nair, Viji ^a   Saha, Jharna ^a   Atkins, Kevin B ^a   Hodgin, Jeffrey B ^a   Saunders, Thomas L ^a   Myers, Martin G ^a   Werner, Thomas ^a   Kretzler, Matthias ^a   Brosius, Frank C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cell signaling; diabetic nephropathy; inflammation; podocyte

Indexed keywords

FIBRONECTIN; JANUS KINASE 2; JANUS KINASE INHIBITOR; LN 3103801; MESSENGER RNA; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DENSITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; JAK2 GENE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 GENE; THICKNESS; TRANSCRIPTOMICS; TRANSGENE; UPREGULATION; WILD TYPE; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DISEASE EXACERBATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; URINE;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBRONECTINS; GLOMERULAR BASEMENT MEMBRANE; HUMANS; JANUS KINASE 2; MALE; MICE; MICE, 129 STRAIN; MICE, TRANSGENIC; PODOCYTES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85019838760     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.03.027     Document Type: Article

References (33)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: National Institutes of Health; 2013.
2. Brosius, F.C. 3rd, Alpers, C.E., Bottinger, E.P., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20 (2009), 2503–2512.
3. Hodgin, J.B., Nair, V., Zhang, H., et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 62 (2013), 299–308.
4. Berthier, C.C., Zhang, H., Schin, M., et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58 (2009), 469–477.
5. O'Shea, J.J., Schwartz, D.M., Villarino, A.V., et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66 (2015), 311–328.
6. Srinivas, S., Watanabe, T., Lin, C.S., et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol, 1, 2001, 4.
7. Chang, J.H., Gurley, S.B., Assessment of diabetic nephropathy in the Akita mouse. Methods Mol Biol 933 (2012), 17–29.
8. Moeller, M.J., Sanden, S.K., Soofi, A., et al. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 35 (2003), 39–42.
9. Niranjan, T., Bielesz, B., Gruenwald, A., et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 14 (2008), 290–298.
10. McGowan, T.A., Zhu, Y., Sharma, K., Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep 4 (2004), 447–454.
11. de Zeeuw, D., Bekker, P., Henkel, E., et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 3 (2015), 687–696.
12. Nelson, P.J., Werner, T., Pathways and promoter networks analysis provides systems topology for systems biology approaches. Semin Nephrol 30 (2010), 477–486.
13. Cartharius, K., Frech, K., Grote, K., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21 (2005), 2933–2942.
14. Amiri, F., Shaw, S., Wang, X., et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 61 (2002), 1605–1616.
15. Marrero, M.B., Banes-Berceli, A.K., Stern, D.M., et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 290 (2006), F762–F768.
16. Banes-Berceli, A.K., Shaw, S., Ma, G., et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 291 (2006), F116–F121.
17. Wang, X., Shaw, S., Amiri, F., et al. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51 (2002), 3505–3509.
18. Banes, A.K., Shaw, S., Jenkins, J., et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286 (2004), F653–F659.
19. Banes-Berceli, A.K., Ketsawatsomkron, P., Ogbi, S., et al. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 293 (2007), H1291–H1299.
20. Woroniecka, K.I., Park, A.S., Mohtat, D., et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 60 (2011), 2354–2369.
21. Brosius, F.C. 3rd, Alpers, C.E., New targets for treatment of diabetic nephropathy: what we have learned from animal models. Curr Opin Nephrol Hypertens 22 (2013), 17–25.
22. Lu, T.C., Wang, Z.H., Feng, X., et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int 76 (2009), 63–71.
23. Tuttle KR. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study. Paper presented at: American Diabetes Association Meeting. June 5–9, 2015; Boston, MA.
24. Zhu, Y., Usui, H.K., Sharma, K., Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Sem Nephrol 27 (2007), 153–160.
25. Liu, R., Zhong, Y., Li, X., et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63 (2014), 2440–2453.
26. Zhuang, S., Regulation of STAT signaling by acetylation. Cell Signal 25 (2013), 1924–1931.
27. Zhang, H., Schin, M., Saha, J., et al. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal Physiol 299 (2010), F91–F98.
28. Mathew, A.V., Zeng, L., Byun, J., et al. Metabolomic profiling of arginine metabolome links altered methylation to chronic kidney disease accelerated atherosclerosis. J Proteomics Bioinform, Suppl 14, 2015.
29. Venkatareddy, M., Wang, S., Yang, Y., et al. Estimating podocyte number and density using a single histologic section. J Am Soc Nephrol 25 (2014), 1118–1129.
30. Grimm, P.C., Nickerson, P., Gough, J., et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14 (2003), 1662–1668.
31. Jensen, E.B., Gundersen, H.J., Osterby, R., Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 115 (1979), 19–33.
32. Ramage, I.J., Howatson, A.G., McColl, J.H., et al. Glomerular basement membrane thickness in children: a stereologic assessment. Kidney Int 62 (2002), 895–900.
33. Zhang, H., Saha, J., Byun, J., et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 295 (2008), F1071–F1081.